pertuzumab (Perjeta) -

pertuzumab (Perjeta)
Information type: Guidance
Source: Scottish Medicines Consortium
Specialities: Cancers
Summary
The SMC does not recommend pertuzumab for use in NHS Scotland, in combination with trastuzumab and chemotherapy for neoadjuvant treatment of adults with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence.
UKMi comment
The submitting company did not present a sufficiently robust economic analysis to gain acceptance by the SMC.
Related links:

Terms and Conditions

For feedback or enquiries relating to this service please email: medicinesresources@gstt.nhs.uk